Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemokine receptor antagonists enhance morphine's antinociceptive effect but not respiratory depression.

Life sciences·2021
Same author

Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.

Molecules (Basel, Switzerland)·2021
Same author

Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.

Handbook of experimental pharmacology·2020
Same author

Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management.

Military medicine·2020
Same author

Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

European journal of pharmacology·2019
Same author

Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB<sub>1</sub> and CB<sub>2</sub> receptors.

British journal of pharmacology·2019

Related Experiment Video

Updated: May 30, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Buprenorphine: the basic pharmacology revisited.

Alan Cowan1

  • 1From the Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA.

Journal of Addiction Medicine
|July 20, 2011
PubMed
Summary
This summary is machine-generated.

Buprenorphine is a key medication for pain relief and opioid dependence treatment. This study reviews its efficacy, safety, and withdrawal effects, offering new insights into its clinical use.

More Related Videos

A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration
11:16

A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration

Published on: February 6, 2014

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm
08:29

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm

Published on: June 7, 2018

Related Experiment Videos

Last Updated: May 30, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration
11:16

A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration

Published on: February 6, 2014

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm
08:29

Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm

Published on: June 7, 2018

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pain Management

Background:

  • Buprenorphine's historical use as an analgesic.
  • Its current role in managing opioid dependence.
  • Understanding buprenorphine's "partial agonist" classification.

Purpose of the Study:

  • To summarize buprenorphine's background and current applications.
  • To discuss its efficacy as a "partial agonist" in pain relief.
  • To present current data on respiratory effects and withdrawal.

Main Methods:

  • Literature review of buprenorphine's historical and current use.
  • Analysis of efficacy data from animal models and clinical studies.
  • Presentation of new data on respiratory depression and withdrawal.

Main Results:

  • Buprenorphine's established role in analgesia and opioid dependence.
  • Discussion of its "partial agonist" properties and clinical relevance.
  • Updated information on respiratory depressant effects and withdrawal syndrome.

Conclusions:

  • Buprenorphine is a versatile medication with established benefits.
  • Further research clarifies its "partial agonist" mechanism and safety profile.
  • New data informs clinical management and understanding of buprenorphine's effects.